EB-1A evaluation (Pharmaceutical research background)

Hello,

I appreciate the guidance that you have provided on your website, it is very helpful.

I am currently working as the Director of Clinical Operations at a major pharmaceutical company. I am the project lead to develop an anticancer agent, a tyrosine kinase inhibitor, as a treatment option for patients with acute myelogenous leukemia (AML) that have FLT3 mutations and for patients with gastrointestinal stromal tumors (GIST) that have the PDGFRAD842V mutations. I now have a total of 8 peer reviewed publications, 33 conference abstracts and 1 book chapter.

I obtained my MS degree in biomedical engineering from a well know University in the United States. In these two years, I accomplished two first author publications (citations 17 and 14, respectively), six poster presentations, including recipient of graduate Dean’s award and a book chapter comprising of my research thesis on biomarker determination with next-generation DNA sequencing devices using nanopores. In addition to academic achievement, I was the elected president of Biomedical Engineering Students Society (BMESS) and secretary of the University chess club. My achievements were recognized by my university and I was awarded a “University Scholar” award, given to the overall top 1 % of the entire school.

Soon after my graduation, I started working for a service business involved in conducting clinical trials. In the first month, I was awarded, employee of the month for significantly exceeding expectations in accelerating patient recruitment for ongoing clinical trials. Following this, I was offered a position in the sister start-up pharmaceutical company to work alongside the CEO. Being the first employee, I had to manage and balance a number of aspects of drug development including conducting due-diligence, preclinical research, clinical research, manufacturing, regulatory, conferences, etc. The broad spectrum of activities and hands on experience allowed me to grow both personally and professionally.

As a researcher this allowed me to become an expert in a biomarker driven bsubset of oncology: FLT3+ AML and PDGFRAD842V mutations driven GIST. I now work closely with key opinion leaders in these fields both in US and internationally. I now have a total of 8 peer reviewed publications (Citations of 49, 36, 33, for top 3 non-first author publications), 33 conference abstracts and 1 book chapter. In addition, I have memberships in American association of cancer research, American society of clinical oncologist, American society of hematologist, and Biomedical engineering students society.

Based on my achievements I believe there is likelihood that I could get an approval under the EB-1A category, with an appropriate support package. I am fully committed to provide you any information needed to help establish this goal. I have attached my CV for further considerations. Please provide an honest opinion if there is a likelihood for me to get an EB-1 approval.

I am looking forward to your reply. Thank you very much for your time and consideration. 

I have 7 top experts that will provide a reference letter for me detailing my expertise.

 —

Regards

Anonymous